PAGE> 1
__________________________________
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________________________________
FORM 10-Q/A
AMENDMENT NO. 1
_X_ QUARTERLY REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 1996
OR
___ TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File No. 0-15271
___________
CISTRON BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
___________
Delaware 22-2487972
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification Number)
10 Bloomfield Avenue, Pine Brook, New Jersey 07058
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:
(201) 575-1700
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 and 15 (d) of the Securities Exchange Act
of 1934 during the preceding 12 months and (2) has been subject to such
filing requirements for the past 90 days.
Yes _X_ No ___
The aggregate number of Registrant's outstanding shares on May 10, 1996
was 26,882,990 shares of Common Stock, $.01 par value.
Page 1 of 12 pages.
<PAGE> 2
<TABLE>
<CAPTION>
CISTRON BIOTECHNOLOGY, INC.
(A Development Stage Company)
INDEX
<S> <C>
PAGE
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Balance sheets as of March 31, 1996 and June 30, 1995 3
Statements of operations for the three months and nine
months ended March 31, 1996 and 1995.................. 4
Statements of cash flow for the nine months ended
March 31, 1996 and 1995............................... 6
Notes to financial statements......................... 7
Item 2. Management's discussion and analysis of results of
operations and financial condition.................... 8
PART II - OTHER INFORMATION................................... 11
Signatures............................................ 12
Cistron Biotechnology, Inc. hereby amends Part II, Item 6.
of the Quarterly Reports on Form 10-Q for the nine months
ended March 31, 1996.
2
</TABLE>
<PAGE> 3
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
a. Exhibits. 27 FDS
11
<PAGE> 12
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: Jul 15, 1996 CISTRON BIOTECHNOLOGY, INC.
(Registrant)
__________
Bruce C. Galton
President, Chief Operating
and Financial Officer,
Secretary and Treasurer
(Principal Financial and
Accounting Officer)
12
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This Schedule contains summary financial information taken from the balance
sheet as of March 31, 1996 and the statement of operations for the nine-month
period ended March 31, 1996, and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-1996
<PERIOD-START> JUL-01-1995
<PERIOD-END> MAR-31-1996
<CASH> 469,057
<SECURITIES> 0
<RECEIVABLES> 142,416
<ALLOWANCES> 0
<INVENTORY> 6,497
<CURRENT-ASSETS> 620,221
<PP&E> 728,998
<DEPRECIATION> 720,043
<TOTAL-ASSETS> 681,646
<CURRENT-LIABILITIES> 342,327
<BONDS> 0
0
0
<COMMON> 268,830
<OTHER-SE> (543,515)
<TOTAL-LIABILITY-AND-EQUITY> 681,646
<SALES> 476,813
<TOTAL-REVENUES> 800,056
<CGS> 248,037
<TOTAL-COSTS> 1,580,304
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (780,248)
<INCOME-TAX> 0
<INCOME-CONTINUING> (780,248)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (780,248)
<EPS-PRIMARY> (.03)
<EPS-DILUTED> (.03)
</TABLE>
